Блокаторы рецепторов ангиотензина II в лечении артериальной гипертензии у пациентов с коморбидной патологией: возможности кандесартана

1. Демографический ежегодник России. 2013. http://www.gks.ru/bgd/regl/ B13_16/Main.htm / Demograficheskii ezhegodnik Rossii. 2013. http://www.gks.ru/bgd/regl/ B13_16/Main.htm [in Russian]
2. Трухан Д.И., Филимонов С.Н. Болезни сердечно-сосудистой системы: клиника, диагностика и лечение. СПб.: СпецЛит, 2016. / Trukhan D.I., Filimonov S.N. Bolezni serdechno-sosudistoi sistemy: klinika, diagnostika i lechenie. SPb.: SpetsLit, 2016. [in Russian]
3. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50. / Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. i dr. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiol. zhurn. 2006; 4: 45–50. [in Russian]
4. Шальнова С., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии. Врач. 2009; 12: 39–42. / Shal'nova S., Kukushkin S., Manoshkina E., Timofeeva T. Arterial'naia gipertenziia i priverzhennost' terapii. Vrach. 2009; 12: 39–42. [in Russian]
5. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Общество специалистов по сердечной недостаточности. Российское кардиологическое общество. 2016. http://ossn.ru/upload/medialibrary/003/97_30012017.pdf / Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Obshchestvo spetsialistov po serdechnoi nedostatochnosti. Rossiiskoe kardiologicheskoe obshchestvo. 2016. http://ossn.ru/upload/medialibrary/003/97_30012017.pdf [in Russian]
6. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Рос. кардиол. журн. 2016; 8: 7–13. / Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13. [in Russian]
7. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 7 (81): 379–472. / Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 7 (81): 379–472. [in Russian]
8. Трухан Д.И., Тарасова Л.В. Оптимизация лекарственной терапии ишемической болезни сердца и артериальной гипертензии: выбор ингибитора ангиотензинпревращающего фермента. Системные гипертензии. 2014; 11 (1): 73–7. / Trukhan D.I., Tarasova L.V. Optimization of drug therapy of coronary heart disease and arterial hypertension: choice angiotensin-converting enzyme inhibitors. Systemic Hypertension. 2014; 11 (1): 73–7. [in Russian]
9. Рекомендации Европейского общества по АГ. 2013. http://gipertonik.ru/recommendation-european-society. / Rekomendatsii Evropeiskogo obshchestva po AG. 2013. http://gipertonik.ru/recommendation-european-society. [in Russian]
10. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр), 2010. Системные гипертензии. 2010; 7 (3): 6–26. / Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr), 2010. Systemic Hypertension. 2010; 7 (3): 6–26. [in Russian]
11. Трухан Д.И. Блокаторы рецепторов к ангиотензину II в лечении артериальной гипертензии у пациентов с сопутствующей патологией: фокус внимания на кандесартан. Системные гипертензии. 2014; 11 (3): 24–9. / Trukhan D.I. Angiotensin II receptor blockers in the treatment of arterial hypertension in patients with concomitant pathology: focus on candesartan. Systemic Hypertension. 2014; 11 (3): 24–9. [in Russian]
12. Hubner R, Hogemann AM, Sunzel M, Riddell JC. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S19–S25.
13. Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil – possible mechanisms of long-term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75–S80.
14. Unger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Press 2000; 9 (Suppl. 1): 14–8.
15. Vauquelin G, Fierens FL, Verheijen I et al. Distinctions between non-peptide angiotensin II AT1-receptor antagonists. JRAAS 2001; 2 (Suppl. 1): S24–S31.
16. Unger T. Inhibiting renin-angiotensin in the brain: the possible therapeutic implications. Blood Press 2001; 10 (Suppl. 1): 12–6.
17. Van Lier JJ, van Heiningen PN, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S27–S28.
18. Кобалава Ж.Д., Склизкова Л.А., Тарапата Н.П. Обоснование, опыт и перспективы применения кандесартана цилексетила. Клин. фармакология и терапия. 2001; 1: 92–6. / Kobalava Zh.D., Sklizkova L.A., Tarapata N.P. Obosnovanie, opyt i perspektivy primeneniia kandesartana tsileksetila. Klin. farmakologiia i terapiia. 2001; 1: 92–6. [in Russian]
19. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
20. Остроумова О.Д., Бондарец О.В., Гусева Т.Ф. Преимущества кандесартана в лечении артериальной гипертонии. Системные гипертензии. 2014; 11 (2): 62–6. / Ostroumova O.D., Bondarets O.V., Guseva T.F. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 11 (2): 62–6. [in Russian]
21. Sakima A, Kita T, Nakada S et al. Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers. Clin Exp Hypertens 2014; 36 (1): 40–5.
22. Кириченко А.А. Антагонист рецепторов ангиотензина II кандесартан в арсенале терапевта. Consilium Medicum. 2016; 18 (10): 76–81. / Kirichenko A.A. Angiotensin II receptor antagonist – candesartan in the arsenal of therapist. Consilium Medicum. 2016; 18 (10): 76–81. [in Russian]
23. Добрынина Н.В. Место кандесартана в современной кардиологии. Consilium Medicum. 2017; 19 (1): 69–72. / Dobrynina N.V. Place of candesartan in modern cardiology. Consilium Medicum. 2017; 19 (1): 69–72. [in Russian]
24. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatment and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563–74.
25. Morgensen E, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440–4.
26. Bakris G, Gradman A, Reif M et al. and the CLAIM Study Investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens 2001; 3: 16–21.
27. Gradman AH, Lewin A, Bowling BT et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52–7.
28. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochloro-thiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS-Study. Clin Drug Invest 2000; 19: 239–46.
29. Vidt DG, White WB, Ridley E et al and the CLAIM Study investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
30. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
31. Zhenfeng Z, Huilan S, Junya J et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; 12 (3): 365–74.
32. Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875–86.
33. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.
34. Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000; 13 (5 Pt 1): 504–11.
35. Escobar C, Barrios V, Calderon A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10: 208–14.
36. Imbs JL, Nisse-Durgeat S. French Collaborative Candesartan Study Group Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. Int J Clin Pract 2005; 59: 78–84.
37. Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22 (Suppl. 1): 29–37.
38. Weisser B, Gerwe M, Braun M, Funken C. Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals. Arzneimittelforschung 2005; 55 (9): 505–13.
39. Grassi G, Seravalle G, Dell’Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761–9.
40. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM–Alternative trial. Lancet 2003; 362 (9386): 772–6.
41. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM – Added trial. Lancet 2003; 362 (9386): 767–71.
42. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003; 362 (9386): 777–81.
43. Pfeffer MF, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: CHARM-Overall program. Lancet 2003; 362: 759–66.
44. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–31.
45. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
46. Ono Y, Mizuno K, Takahashi M et al. Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. Fukushima J Med Sci 2013; 59 (2): 69–75.
47. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; p. 1195–201.
48. Schrader J, Luders S, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699–703.
49. Ishrat T, Pillai B, Ergul A et al. Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. Neurochem Res 2013; 38 (12): 2668–77.
50. Soliman S, Ishrat T, Pillai A et al. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B. J Pharmacol Exp Ther 2014; 349 (3): 444–57.
51. Barakat W, Safwet N, El-Maraghy NN, Zakaria MN. Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade. Eur J Pharmacol 2014; 724: 43–50.
52. Sunami E, Nomura K, Nishiyama Y, Katayama Y. Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. J Nippon Med Sch 2016; 83 (6): 272–6.
53. Mazza A, Sacco AP, Townsend DM et al. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis. Biomed Pharmacother 2017; 90: 665–9.
54. Белоусов Ю.Б., Белоусов Д.Ю., Бекетов А.С. Клинико-экономический анализ применения кандесартана у пожилых пациентов с артериальной гипертонией для предотвращения развития нефатального инсульта мозга. Болезни сердца и сосудов. 2009; 3: 22–7. / Belousov Iu.B., Belousov D.Iu., Beketov A.S. Kliniko-ekonomicheskii analiz primeneniia kandesartana u pozhilykh patsientov s arterial'noi gipertoniei dlia predotvrashcheniia razvitiia nefatal'nogo insul'ta mozga. Bolezni serdtsa i sosudov. 2009; 3: 22–7. [in Russian]
55. Sjolie AK, Porta M, Parving HH et al. The DIabetic REtinopathy Candersantan Trials (DIRECT) Programme: baseline characteristics. JRAAS 2005; 6 (1): 25–32.
56. Шестакова М.В., Шамхалова М.Ш. Блокада ренин-ангиотензиновой системы в профилактике и лечении диабетической ретинопатии: результаты исследования DIRECT. Consilium Medicum. 2008; 10 (9). / Shestakova M.V., Shamkhalova M.Sh. Blokada renin-angiotenzinovoi sistemy v profilaktike i lechenii diabeticheskoi retinopatii: rezul'taty issledovaniia DIRECT. Consilium Medicum. 2008; 10 (9). [in Russian]
57. Torres RJ, Luchini A, Torres RR et al. Effect of candesartan on the expression of sclera-choroidal intercellular adhesion molecule-1 in hypercholesterolemic models. Clinics (Sao Paulo) 2014; 69 (2): 145–9.
58. Долгих В.Т., Наумов Д.В., Ахмедов В.А., Дворников В.Э. Тактика профилактики фибрилляции предсердий при артериальной гипертонии. Клин. медицина. 2009; 10: 17–9. / Dolgikh V.T., Naumov D.V., Akhmedov V.A., Dvornikov V.E. Taktika profilaktiki fibrilliatsii predserdii pri arterial'noi gipertonii. Klin. meditsina. 2009; 10: 17–9. [in Russian]
59. Преображенский Д.В., Патарая С.А. Кандесартан – блокатор АТ1-ангиотензиновых рецепторов длительного действия: особенности фармакологии и опыт клинического применения. Consilium Medicum. 2006; 8 (11): 117–25. / Preobrazhenskii D.V., Pataraia S.A. Kandesartan – blokator AT1-angiotenzinovykh retseptorov dlitel'nogo deistviia: osobennosti farmakologii i opyt klinicheskogo primeneniia. Consilium Medicum. 2006; 8 (11): 117–25. [in Russian]
60. Чазова И.Е., Чихладзе Н.М., Колос И.П. и др. Эффективность применения кандесартана при гипертонической болезни и при нефрогенной артериальной гипертонии. Кардиоваск. терапия и профилактика. 2008; 7: 34–8. / Chazova I.E., Chikhladze N.M., Kolos I.P. i dr. Effektivnost' primeneniia kandesartana pri gipertonicheskoi bolezni i pri nefrogennoi arterial'noi gipertonii. Kardiovask. terapiia i profilaktika. 2008; 7: 34–8. [in Russian]
61. Чихладзе Н.М., Сивакова О.А., Блинова Е.В. и др. Эффективность применения кандесартана при гипертонической болезни и нефрогенной артериальной гипертонии. Системные гипертензии. 2008; 5 (4): 43–6. / Chikhladze N.M., Sivakova O.A., Blinova E.V. et al. Effektivnost' primeneniia kandesartana pri gipertonicheskoi bolezni i nefrogennoi arterial'noi gipertonii. Systemic Hypertension. 2008; 5 (4): 43–6. [in Russian]
62. Муркамилов И.Т., Айтбаев К.А., Реджапова Н.А., Райимжанов З.Р. Нефро- и церебропротекция при хронической болезни почек: возможности кандесартана. Кардиология. 2017; 6: 69–75. / Murkamilov I.T., Aitbaev K.A., Redzhapova N.A., Raiimzhanov Z.R. Nefro- i tserebroprotektsiia pri khronicheskoi bolezni pochek: vozmozhnosti kandesartana. Kardiologiia. 2017; 6: 69–75. [in Russian]
63. Fridman K, Andersson OK, Wysocki M et al. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol 1998; 54: 497–501.
64. Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hypertens 2000; 13: 1045–8.
65. Fridman K, Elmfeldt D, Wysocki M et al. Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. Blood Press 2002; 11 (4): 244–52.
66. Matsuda H, Hayashi K, Homma K et al. Differing antiproteinuric action of candesartan and losartan in chonic renal disease. Hypertens Res 2003; 26 (11): 875–80.
67. Matsuda H, Hayashi K, Saruta T. l. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens 2003; 17 (4): 271–6.
68. Rossing K, Christensen PK, Hansen BV et al. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy. Diabetic Care 2003; 26: 150–5.
69. Bramlage P, Schönrock E, Odoj P. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovasc Disord 2008; 8: 30.
70. Смирнов А.В., Шилов Е.М, Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клин. нефрология. 2012; 4: 4–26. / Smirnov A.V., Shilov E.M, Dobronravov V.A. i dr. Natsional'nye rekomendatsii. Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Klin. nefrologiia. 2012; 4: 4–26. [in Russian]
71. De Rosa MJ. Angiotensin II receptor blockers and cardioprotection. Vasc Health Risk Manag 2010; 6: 1047–63.
72. Burgess E, Muirhead N, Rene de Cotret P et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893–900.
73. Щулькин А.В., Филимонова А.А., Трунина Т.П. Фармакотерапия артериальной гипертензии у пациентов на гемодиализе. Наука молодых. 2016; 3: 28–34. / Shchul'kin A.V., Filimonova A.A., Trunina T.P. Farmakoterapiia arterial'noi gipertenzii u patsientov na gemodialize. Nauka molodykh. 2016; 3: 28–34. [in Russian]
74. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
75. De Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997; 11 (Suppl. 2): S37–42.
76. Buter H, Navis GY, Woittiez A et al. Pharmacokinetiec and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol 1999; 54: 953–8.
77. Kurokawa K, Abe K, Sarata T et al. Antiproteinuric effect of candesartan cilexetil in patients with chonic glomerulonephritis. J Renin Angiotensin Aldosterone Syst 2002; 3 (3): 167–75.
78. Imura A, Kusano E, Tanba K et al. Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis. Nippon Jinzo Gakkai Shi 2003; 45 (5): 439–44.
79. Carroll RP, Riceman M, Hope CM et al. Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan. Hum Immunol 2016; 77 (12): 1154–8.
80. Zhao LQ, Huang JL, Yu Y et al. Candesartan inhibits LPS-induced expression increase of toll-like receptor 4 and downstream inflammatory factors likely via angiotensin II type 1 receptor independent pathway in human renal tubular epithelial cells. Sheng Li Xue Bao 2013; 65 (6): 623–30.
81. Толмачев В.В., Симоненко В.Б., Медведев И.Н. Динамика активности первичного гемостаза у больных артериальной гипертонией при метаболическом синдроме на фоне лечения кандесартаном. Клин. медицина. 2011; 3: 35–8. / Tolmachev V.V., Simonenko V.B., Medvedev I.N. Dinamika aktivnosti pervichnogo gemostaza u bol'nykh arterial'noi gipertoniei pri metabolicheskom sindrome na fone lecheniia kandesartanom. Klin. meditsina. 2011; 3: 35–8. [in Russian]
82. Гапон Л.И., Мусихина Н.А., Петелина Т.И. и др. Клиническая эффективность кандесартана и его влияние на упругость сосудистой стенки, липидный профиль и процессы перекисного окисления липидов у женщин с метаболическими нарушениями в период менопаузы. Мед. альманах. 2011; 3: 103–7. / Gapon L.I., Musikhina N.A., Petelina T.I. i dr. Klinicheskaia effektivnost' kandesartana i ego vliianie na uprugost' sosudistoi stenki, lipidnyi profil' i protsessy perekisnogo okisleniia lipidov u zhenshchin s metabolicheskimi narusheniiami v period menopauzy. Med. al'manakh. 2011; 3: 103–7. [in Russian]
83. Stovner LJ, Linde M, Gravdahl GB et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2013; 34 (7): 523–32.
84. Hofni A, El-Moselhy MA, Taye A, Khalifa MM. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. Eur J Pharmacol 2014; 744: 173–82.
85. Kabel AM, Elkhoely AA. Ameliorative Effect of Coenzyme Q10 and/or Candesartan on Carboplatin-Induced Nephrotoxicity: Roles of Apoptosis, Transforming Growth Factor-Β1, Nuclear Factor Kappa-B And The Nrf2/HO-1 Pathway. Asian Pac J Cancer Prev 2017; 18 (6): 1629–36.
86. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13 
(Suppl. 1): S69–S73.
87. Остроумова О.Д., Средняков А.В., Смолярчук Е.А. Комбинация антагониста рецепторов к ангиотензину II с диуретиком: эффективность, безопасность, показания к назначению. Системные гипертензии. 2010; 7 (4): 21–4. / Ostroumova O.D., Sredniakov A.V., Smoliarchuk E.A. A combination of an angiotensin II receptor antagonist and a diuretic: efficacy, safety, indications for use. Systemic Hypertension. 2010; 7 (4): 21–4. [in Russian]
88. Mugellini A, Nieswandt V. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. Expert Opin Pharmacother 2012; 13 (18): 2699–709.
89. Setiawati A, Pohan T. Safety and effectiveness of candesartan and candesartan/HCT fixed dose combination in patients with hypertension. Acta Med Indones 2013; 45 (3): 193–201.
90. Bramlage P, Buhck H, Zemmrich C. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact. Clin Drug Investig 2014; 34 (4): 241–9.
91. Sakima A, Kita T, Nakada S et al. Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers. Clin Exp Hypertens 2014; 36 (1): 40–5.
92. Чазова И.Е. Место блокаторов рецепторов ангиотензина II 1-го типа в современной терапии артериальной гипертонии. Consilium Medicum. 2008; 10 (11): 11–4. / Chazova I.E. Mesto blokatorov retseptorov angiotenzina II 1-go tipa v sovremennoi terapii arterial'noi gipertonii. Consilium Medicum. 2008; 10 (11): 11–4. [in Russian]
93. Драпкина О.М., Дикур О.Н. Кандесартан в профилактике сердечно-сосудистых катастроф: акцент на предупреждение инсульта катастроф: акцент на предупреждение инсульта. Системные гипертензии. 2009; 6 (4): 66–9. / Drapkina O.M., Dikur O.N. Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke. Systemic Hypertension. 2009; 6 (4): 66–9. [in Russian]
94. Трухан Д.И., Тарасова Л.В. Рациональная фармакотерапия и лекарственная безопасность в кардиологии. Справочник поликлинического врача. 2013; 5: 21–6. / Trukhan D.I., Tarasova L.V. Ratsional'naia farmakoterapiia i lekarstvennaia bezopasnost' v kardiologii. Handbook for Practitioners Doctors. 2013; 5: 21–6. [in Russian]
95. Трухан Д.И., Викторова И.А. Внутренние болезни: Кардиология. Ревматология. М.: Медицинское информационное агентство, 2013. / Trukhan D.I., Viktorova I.A. Vnutrennie bolezni: Kardiologiia. Revmatologiia. M.: Meditsinskoe informatsionnoe agentstvo, 2013. [in Russian]
96. Морозова Т.Е., Андрущишина Т.Б., Гонтаренко С.В. Возможности блокаторов рецепторов ангиотензина II (сартанов) у больных артериальной гипертензией. Системные гипертензии. 2014; 11 (3): 33–8. / Morozova T.E., Andrushchishina T.B., Gontarenko S.V. Possibilities ARB II (sartans) in hypertensive patients. Systemic Hypertension. 2014; 11 (3): 33–8. [in Russian]
97. Чихладзе Н.М., Чазова И.Е. Артериальная гипертония и почки. Consilium Medicum. 2015; 17 (10): 8–12. / Chikhladze N.M., Chazova I.E. Arterial hypertension and the kidney. Consilium Medicum. 2015; 17 (10): 8–12. [in Russian]
98. Рыбачкова Ю.В. Клинические аспекты применения кандесартана. Consilium Medicum. 2016; 18 (10): 61–5. / Rybachkova Iu.V. Clinical aspects of application of candesartan. Consilium Medicum. 2016; 18 (10): 61–5. [in Russian]
99. Виноградова Н.Г. Эффективность специализированной медицинской помощи больным хронической сердечной недостаточностью. Сердечная недостаточность. 2017; 2: 122–32. / Vinogradova N.G. Effektivnost' spetsializirovannoi meditsinskoi pomoshchi bol'nym khronicheskoi serdechnoi nedostatochnost'iu. Serdechnaia nedostatochnost'. 2017; 2: 122–32. [in Russian]
100. Трухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности. Справочник поликлинического врача. 2015; 1: 26–31. / Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
101. Трухан Д.И. Оригиналы и генерики: перезагрузка в свете экономического кризиса. Справочник поликлинического врача. 2012; 4: 32–6. / Trukhan D.I. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Handbook for Practitioners Doctors. 2012; 4: 32–6. [in Russian]
102. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 15 (11): 45–9. / Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
103. Благодаря дженерикам американцы сэкономили $254 млрд в 2014 году. http://pharmapractice.ru/121342 / Blagodaria dzhenerikam amerikantsy sekonomili $254 mlrd v 2014 godu. http://pharmapractice.ru/121342 [in Russian]

________________________________________________

1. Demograficheskii ezhegodnik Rossii. 2013. http://www.gks.ru/bgd/regl/ B13_16/Main.htm [in Russian]
2. Trukhan D.I., Filimonov S.N. Bolezni serdechno-sosudistoi sistemy: klinika, diagnostika i lechenie. SPb.: SpetsLit, 2016. [in Russian]
3. Shal'nova S.A., Balanova Iu.A., Konstantinov V.V. i dr. Arterial'naia gipertoniia: rasprostranennost', osvedomlennost', priem antigipertenzivnykh preparatov i effektivnost' lecheniia sredi naseleniia Rossiiskoi Federatsii. Ros. kardiol. zhurn. 2006; 4: 45–50. [in Russian]
4. Shal'nova S., Kukushkin S., Manoshkina E., Timofeeva T. Arterial'naia gipertenziia i priverzhennost' terapii. Vrach. 2009; 12: 39–42. [in Russian]
5. Klinicheskie rekomendatsii. Khronicheskaia serdechnaia nedostatochnost' (KhSN). Obshchestvo spetsialistov po serdechnoi nedostatochnosti. Rossiiskoe kardiologicheskoe obshchestvo. 2016. http://ossn.ru/upload/medialibrary/003/97_30012017.pdf [in Russian]
6. Fomin I.V. Khronicheskaia serdechnaia nedostatochnost' v Rossiiskoi Federatsii: chto segodnia my znaem i chto dolzhny delat'. Ros. kardiol. zhurn. 2016; 8: 7–13. [in Russian]
7. Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsional'nye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (chetvertyi peresmotr). Serdechnaia nedostatochnost'. 2013; 7 (81): 379–472. [in Russian]
8. Trukhan D.I., Tarasova L.V. Optimization of drug therapy of coronary heart disease and arterial hypertension: choice angiotensin-converting enzyme inhibitors. Systemic Hypertension. 2014; 11 (1): 73–7. [in Russian]
9. Rekomendatsii Evropeiskogo obshchestva po AG. 2013. http://gipertonik.ru/recommendation-european-society. [in Russian]
10. Rossiiskoe meditsinskoe obshchestvo po arterial'noi gipertonii (RMOAG), Vserossiiskoe nauchnoe obshchestvo kardiologov (VNOK). Diagnostika i lechenie arterial'noi gipertenzii. Rossiiskie rekomendatsii (chetvertyi peresmotr), 2010. Systemic Hypertension. 2010; 7 (3): 6–26. [in Russian]
11. Trukhan D.I. Angiotensin II receptor blockers in the treatment of arterial hypertension in patients with concomitant pathology: focus on candesartan. Systemic Hypertension. 2014; 11 (3): 24–9. [in Russian]
12. Hubner R, Hogemann AM, Sunzel M, Riddell JC. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S19–S25.
13. Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil – possible mechanisms of long-term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75–S80.
14. Unger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Press 2000; 9 (Suppl. 1): 14–8.
15. Vauquelin G, Fierens FL, Verheijen I et al. Distinctions between non-peptide angiotensin II AT1-receptor antagonists. JRAAS 2001; 2 (Suppl. 1): S24–S31.
16. Unger T. Inhibiting renin-angiotensin in the brain: the possible therapeutic implications. Blood Press 2001; 10 (Suppl. 1): 12–6.
17. Van Lier JJ, van Heiningen PN, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S27–S28.
18. Kobalava Zh.D., Sklizkova L.A., Tarapata N.P. Obosnovanie, opyt i perspektivy primeneniia kandesartana tsileksetila. Klin. farmakologiia i terapiia. 2001; 1: 92–6. [in Russian]
19. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
20. Ostroumova O.D., Bondarets O.V., Guseva T.F. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 11 (2): 62–6. [in Russian]
21. Sakima A, Kita T, Nakada S et al. Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers. Clin Exp Hypertens 2014; 36 (1): 40–5.
22. Kirichenko A.A. Angiotensin II receptor antagonist – candesartan in the arsenal of therapist. Consilium Medicum. 2016; 18 (10): 76–81. [in Russian]
23. Dobrynina N.V. Place of candesartan in modern cardiology. Consilium Medicum. 2017; 19 (1): 69–72. [in Russian]
24. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatment and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563–74.
25. Morgensen E, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440–4.
26. Bakris G, Gradman A, Reif M et al. and the CLAIM Study Investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens 2001; 3: 16–21.
27. Gradman AH, Lewin A, Bowling BT et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52–7.
28. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochloro-thiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS-Study. Clin Drug Invest 2000; 19: 239–46.
29. Vidt DG, White WB, Ridley E et al and the CLAIM Study investigators. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001; 15: 475–80.
30. Hasegawa H, Takano H, Kameda Y et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
31. Zhenfeng Z, Huilan S, Junya J et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; 12 (3): 365–74.
32. Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875–86.
33. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.
34. Malmqvist K, Kahan T, Dahl M. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000; 13 (5 Pt 1): 504–11.
35. Escobar C, Barrios V, Calderon A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10: 208–14.
36. Imbs JL, Nisse-Durgeat S. French Collaborative Candesartan Study Group Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. Int J Clin Pract 2005; 59: 78–84.
37. Minatoguchi S, Aoyama T, Kawai N et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22 (Suppl. 1): 29–37.
38. Weisser B, Gerwe M, Braun M, Funken C. Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals. Arzneimittelforschung 2005; 55 (9): 505–13.
39. Grassi G, Seravalle G, Dell’Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761–9.
40. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM–Alternative trial. Lancet 2003; 362 (9386): 772–6.
41. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM – Added trial. Lancet 2003; 362 (9386): 767–71.
42. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003; 362 (9386): 777–81.
43. Pfeffer MF, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: CHARM-Overall program. Lancet 2003; 362: 759–66.
44. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–31.
45. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
46. Ono Y, Mizuno K, Takahashi M et al. Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. Fukushima J Med Sci 2013; 59 (2): 69–75.
47. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; p. 1195–201.
48. Schrader J, Luders S, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34: 1699–703.
49. Ishrat T, Pillai B, Ergul A et al. Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. Neurochem Res 2013; 38 (12): 2668–77.
50. Soliman S, Ishrat T, Pillai A et al. Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: role of vascular endothelial growth factors A and B. J Pharmacol Exp Ther 2014; 349 (3): 444–57.
51. Barakat W, Safwet N, El-Maraghy NN, Zakaria MN. Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade. Eur J Pharmacol 2014; 724: 43–50.
52. Sunami E, Nomura K, Nishiyama Y, Katayama Y. Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. J Nippon Med Sch 2016; 83 (6): 272–6.
53. Mazza A, Sacco AP, Townsend DM et al. Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis. Biomed Pharmacother 2017; 90: 665–9.
54. Belousov Iu.B., Belousov D.Iu., Beketov A.S. Kliniko-ekonomicheskii analiz primeneniia kandesartana u pozhilykh patsientov s arterial'noi gipertoniei dlia predotvrashcheniia razvitiia nefatal'nogo insul'ta mozga. Bolezni serdtsa i sosudov. 2009; 3: 22–7. [in Russian]
55. Sjolie AK, Porta M, Parving HH et al. The DIabetic REtinopathy Candersantan Trials (DIRECT) Programme: baseline characteristics. JRAAS 2005; 6 (1): 25–32.
56. Shestakova M.V., Shamkhalova M.Sh. Blokada renin-angiotenzinovoi sistemy v profilaktike i lechenii diabeticheskoi retinopatii: rezul'taty issledovaniia DIRECT. Consilium Medicum. 2008; 10 (9). [in Russian]
57. Torres RJ, Luchini A, Torres RR et al. Effect of candesartan on the expression of sclera-choroidal intercellular adhesion molecule-1 in hypercholesterolemic models. Clinics (Sao Paulo) 2014; 69 (2): 145–9.
58. Dolgikh V.T., Naumov D.V., Akhmedov V.A., Dvornikov V.E. Taktika profilaktiki fibrilliatsii predserdii pri arterial'noi gipertonii. Klin. meditsina. 2009; 10: 17–9. [in Russian]
59. Preobrazhenskii D.V., Pataraia S.A. Kandesartan – blokator AT1-angiotenzinovykh retseptorov dlitel'nogo deistviia: osobennosti farmakologii i opyt klinicheskogo primeneniia. Consilium Medicum. 2006; 8 (11): 117–25. [in Russian]
60. Chazova I.E., Chikhladze N.M., Kolos I.P. i dr. Effektivnost' primeneniia kandesartana pri gipertonicheskoi bolezni i pri nefrogennoi arterial'noi gipertonii. Kardiovask. terapiia i profilaktika. 2008; 7: 34–8. [in Russian]
61. Chikhladze N.M., Sivakova O.A., Blinova E.V. et al. Effektivnost' primeneniia kandesartana pri gipertonicheskoi bolezni i nefrogennoi arterial'noi gipertonii. Systemic Hypertension. 2008; 5 (4): 43–6. [in Russian]
62. Murkamilov I.T., Aitbaev K.A., Redzhapova N.A., Raiimzhanov Z.R. Nefro- i tserebroprotektsiia pri khronicheskoi bolezni pochek: vozmozhnosti kandesartana. Kardiologiia. 2017; 6: 69–75. [in Russian]
63. Fridman K, Andersson OK, Wysocki M et al. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol 1998; 54: 497–501.
64. Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hypertens 2000; 13: 1045–8.
65. Fridman K, Elmfeldt D, Wysocki M et al. Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. Blood Press 2002; 11 (4): 244–52.
66. Matsuda H, Hayashi K, Homma K et al. Differing antiproteinuric action of candesartan and losartan in chonic renal disease. Hypertens Res 2003; 26 (11): 875–80.
67. Matsuda H, Hayashi K, Saruta T. l. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. J Hum Hypertens 2003; 17 (4): 271–6.
68. Rossing K, Christensen PK, Hansen BV et al. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy. Diabetic Care 2003; 26: 150–5.
69. Bramlage P, Schönrock E, Odoj P. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovasc Disord 2008; 8: 30.
70. Smirnov A.V., Shilov E.M, Dobronravov V.A. i dr. Natsional'nye rekomendatsii. Khronicheskaia bolezn' pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniiu. Klin. nefrologiia. 2012; 4: 4–26. [in Russian]
71. De Rosa MJ. Angiotensin II receptor blockers and cardioprotection. Vasc Health Risk Manag 2010; 6: 1047–63.
72. Burgess E, Muirhead N, Rene de Cotret P et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893–900.
73. Shchul'kin A.V., Filimonova A.A., Trunina T.P. Farmakoterapiia arterial'noi gipertenzii u patsientov na gemodialize. Nauka molodykh. 2016; 3: 28–34. [in Russian]
74. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
75. De Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997; 11 (Suppl. 2): S37–42.
76. Buter H, Navis GY, Woittiez A et al. Pharmacokinetiec and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol 1999; 54: 953–8.
77. Kurokawa K, Abe K, Sarata T et al. Antiproteinuric effect of candesartan cilexetil in patients with chonic glomerulonephritis. J Renin Angiotensin Aldosterone Syst 2002; 3 (3): 167–75.
78. Imura A, Kusano E, Tanba K et al. Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis. Nippon Jinzo Gakkai Shi 2003; 45 (5): 439–44.
79. Carroll RP, Riceman M, Hope CM et al. Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan. Hum Immunol 2016; 77 (12): 1154–8.
80. Zhao LQ, Huang JL, Yu Y et al. Candesartan inhibits LPS-induced expression increase of toll-like receptor 4 and downstream inflammatory factors likely via angiotensin II type 1 receptor independent pathway in human renal tubular epithelial cells. Sheng Li Xue Bao 2013; 65 (6): 623–30.
81. Tolmachev V.V., Simonenko V.B., Medvedev I.N. Dinamika aktivnosti pervichnogo gemostaza u bol'nykh arterial'noi gipertoniei pri metabolicheskom sindrome na fone lecheniia kandesartanom. Klin. meditsina. 2011; 3: 35–8. [in Russian]
82. Gapon L.I., Musikhina N.A., Petelina T.I. i dr. Klinicheskaia effektivnost' kandesartana i ego vliianie na uprugost' sosudistoi stenki, lipidnyi profil' i protsessy perekisnogo okisleniia lipidov u zhenshchin s metabolicheskimi narusheniiami v period menopauzy. Med. al'manakh. 2011; 3: 103–7. [in Russian]
83. Stovner LJ, Linde M, Gravdahl GB et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia 2013; 34 (7): 523–32.
84. Hofni A, El-Moselhy MA, Taye A, Khalifa MM. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. Eur J Pharmacol 2014; 744: 173–82.
85. Kabel AM, Elkhoely AA. Ameliorative Effect of Coenzyme Q10 and/or Candesartan on Carboplatin-Induced Nephrotoxicity: Roles of Apoptosis, Transforming Growth Factor-Β1, Nuclear Factor Kappa-B And The Nrf2/HO-1 Pathway. Asian Pac J Cancer Prev 2017; 18 (6): 1629–36.
86. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13 
(Suppl. 1): S69–S73.
87. Ostroumova O.D., Sredniakov A.V., Smoliarchuk E.A. A combination of an angiotensin II receptor antagonist and a diuretic: efficacy, safety, indications for use. Systemic Hypertension. 2010; 7 (4): 21–4. [in Russian]
88. Mugellini A, Nieswandt V. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy. Expert Opin Pharmacother 2012; 13 (18): 2699–709.
89. Setiawati A, Pohan T. Safety and effectiveness of candesartan and candesartan/HCT fixed dose combination in patients with hypertension. Acta Med Indones 2013; 45 (3): 193–201.
90. Bramlage P, Buhck H, Zemmrich C. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact. Clin Drug Investig 2014; 34 (4): 241–9.
91. Sakima A, Kita T, Nakada S et al. Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers. Clin Exp Hypertens 2014; 36 (1): 40–5.
92. Chazova I.E. Mesto blokatorov retseptorov angiotenzina II 1-go tipa v sovremennoi terapii arterial'noi gipertonii. Consilium Medicum. 2008; 10 (11): 11–4. [in Russian]
93. Drapkina O.M., Dikur O.N. Candesartan in the prevention of cardiovascular catastrophes: emphasis on the pre-vention of stroke. Systemic Hypertension. 2009; 6 (4): 66–9. [in Russian]
94. Trukhan D.I., Tarasova L.V. Ratsional'naia farmakoterapiia i lekarstvennaia bezopasnost' v kardiologii. Handbook for Practitioners Doctors. 2013; 5: 21–6. [in Russian]
95. Trukhan D.I., Viktorova I.A. Vnutrennie bolezni: Kardiologiia. Revmatologiia. M.: Meditsinskoe informatsionnoe agentstvo, 2013. [in Russian]
96. Morozova T.E., Andrushchishina T.B., Gontarenko S.V. Possibilities ARB II (sartans) in hypertensive patients. Systemic Hypertension. 2014; 11 (3): 33–8. [in Russian]
97. Chikhladze N.M., Chazova I.E. Arterial hypertension and the kidney. Consilium Medicum. 2015; 17 (10): 8–12. [in Russian]
98. Rybachkova Iu.V. Clinical aspects of application of candesartan. Consilium Medicum. 2016; 18 (10): 61–5. [in Russian]
99. Vinogradova N.G. Effektivnost' spetsializirovannoi meditsinskoi pomoshchi bol'nym khronicheskoi serdechnoi nedostatochnost'iu. Serdechnaia nedostatochnost'. 2017; 2: 122–32. [in Russian]
100. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
101. Trukhan D.I. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Handbook for Practitioners Doctors. 2012; 4: 32–6. [in Russian]
102. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 15 (11): 45–9. [in Russian]
103. Blagodaria dzhenerikam amerikantsy sekonomili $254 mlrd v 2014 godu. http://pharmapractice.ru/121342 [in Russian]

Д.И.Трухан*1, Е.Л.Давыдов2

1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12;
2 ФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф.Войно-Ясенецкого» Минздрава России. 660022, Россия, Красноярск, ул. Партизана Железняка, д. 1
*dmitry_trukhan@mail.ru

________________________________________________

D.I.Trukhan*1, E.L.Davydov2

1 Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12;
2 V.F.Voino-Yasenetsky Krasnoyarsk State Medical University of the Ministry of Health of the Russian Federation. 660022, Russian Federation, Krasnoyarsk, ul. Partizana Zhelezniaka, d. 1
*dmitry_trukhan@mail.ru